Mesenchymal stem cells not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Lupus Nephritis, Lupus Erythematosus
- Main trialPhase 2
- “The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) obtained from bone marrow for the treatment of adults with active proliferative lupus nephritis. The objective of this study is to evaluate the efficacy of mesenchymal stem cells (MSCs) in achieving a full or partial response in the treatment of Lupus Nephritis (LN) during its induction period.”In the company’s words, NCT03673748 on ClinicalTrials.gov
Other drugs for Lupus Nephritis
- AnifrolumabAstraZeneca · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- IanalumabNovartis · Phase 3
- Mycophenolate MofetilRoche · Phase 3
- ObinutuzumabRoche · Phase 3
- CenerimodViatris Innovation GmbH · Phase 3
Coming up1
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2027 | Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells | |
| Phase 2Completed | 28 Oct 2021 | Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stem Cells |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026